FR2795324B1 - Compositions pharmaceutiques stabilisees - Google Patents

Compositions pharmaceutiques stabilisees

Info

Publication number
FR2795324B1
FR2795324B1 FR0010334A FR0010334A FR2795324B1 FR 2795324 B1 FR2795324 B1 FR 2795324B1 FR 0010334 A FR0010334 A FR 0010334A FR 0010334 A FR0010334 A FR 0010334A FR 2795324 B1 FR2795324 B1 FR 2795324B1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
stabilized pharmaceutical
stabilized
compositions
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0010334A
Other languages
English (en)
Other versions
FR2795324A1 (fr
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2795324(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of FR2795324A1 publication Critical patent/FR2795324A1/fr
Application granted granted Critical
Publication of FR2795324B1 publication Critical patent/FR2795324B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
FR0010334A 2000-01-26 2000-08-04 Compositions pharmaceutiques stabilisees Expired - Lifetime FR2795324B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
FR2795324A1 FR2795324A1 (fr) 2000-12-29
FR2795324B1 true FR2795324B1 (fr) 2002-05-17

Family

ID=9884259

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0010333A Expired - Lifetime FR2804025B1 (fr) 2000-01-26 2000-08-04 Compositions pharmaceutiques stabilisees
FR0010334A Expired - Lifetime FR2795324B1 (fr) 2000-01-26 2000-08-04 Compositions pharmaceutiques stabilisees

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0010333A Expired - Lifetime FR2804025B1 (fr) 2000-01-26 2000-08-04 Compositions pharmaceutiques stabilisees

Country Status (48)

Country Link
US (2) US6548513B1 (fr)
EP (6) EP2774609A1 (fr)
JP (3) JP4800467B2 (fr)
KR (3) KR100388713B1 (fr)
CN (3) CN100528161C (fr)
AP (2) AP1449A (fr)
AR (3) AR025055A1 (fr)
AT (3) AT412063B (fr)
AU (5) AU6580000A (fr)
BE (2) BE1013413A3 (fr)
BG (4) BG65234B1 (fr)
BR (2) BR0003365A (fr)
CA (3) CA2313783C (fr)
CH (2) CH700184B1 (fr)
CL (1) CL2007001807A1 (fr)
CR (3) CR6568A (fr)
CZ (3) CZ298411B6 (fr)
DE (3) DE60001371T2 (fr)
DK (3) DK1223918T3 (fr)
EE (3) EE05221B1 (fr)
ES (2) ES2171123B1 (fr)
FI (3) FI111806B (fr)
FR (2) FR2804025B1 (fr)
GB (3) GB0001621D0 (fr)
HK (6) HK1036935A1 (fr)
HR (3) HRP20020097B1 (fr)
HU (2) HUP0003111A3 (fr)
IL (4) IL150513A0 (fr)
IS (3) IS1940B (fr)
IT (2) ITTO20000780A1 (fr)
ME (4) ME00191B (fr)
MY (2) MY122707A (fr)
NL (2) NL1015858C2 (fr)
NO (4) NO327675B1 (fr)
NZ (2) NZ519774A (fr)
PL (2) PL196808B1 (fr)
PT (3) PT102503B (fr)
RS (1) RS50201B (fr)
RU (2) RU2264210C2 (fr)
SE (2) SE523481C2 (fr)
SI (1) SI1223918T1 (fr)
SK (2) SK283872B6 (fr)
TR (3) TR200201888T2 (fr)
TW (2) TW553749B (fr)
UA (2) UA51853C2 (fr)
WO (2) WO2001054668A1 (fr)
YU (1) YU52902A (fr)
ZA (2) ZA200003998B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
DK1274401T4 (da) † 2000-04-10 2014-09-08 Teva Pharma Stabile farmaceutiske sammensætninger indeholdende 7-substituerede-3,5-dihydroxyheptansyrer eller 7-substituerede-3,5-dihydroxyheptensyrer
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (fr) * 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
AU2003254914A1 (en) * 2002-08-12 2004-03-03 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
WO2005023778A2 (fr) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Procede de preparation de sels calciques de rosuvastatine
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
BRPI0414254B8 (pt) * 2003-09-12 2021-05-25 Amgen Inc composição farmacêutica compreendendo hcl de cinacalceto
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
KR100887264B1 (ko) * 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
WO2005107722A2 (fr) * 2004-05-04 2005-11-17 Rhodia Inc. Phosphate tricalcique directement compressible
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
TWI353981B (en) * 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2007019373A2 (fr) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Nouvelles formulations contenant du fenofibrate et de la statine et procedes de traitement associes
EP1805148A2 (fr) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Intermediaire de rosuvastatine sous forme cristalline
CA2621273C (fr) 2005-09-12 2014-07-29 Actelion Pharmaceuticals Ltd Composition pharmaceutique stable a pyrimidine-sulfamide
CA2626309A1 (fr) * 2005-10-31 2007-05-10 Kowa Co., Ltd. Preparation pharmaceutique contenant de la pitavastine ayant une photostabilite excellente
EP1968593B1 (fr) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Composition pharmaceutique comprenant de l'acide (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoique
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines, d'agent anti-obésité et de glitazones
AP2009005026A0 (en) * 2007-04-09 2009-12-31 Scidose Llc Combinations of statins and anti-obesity agent
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
EP2285353A1 (fr) * 2008-01-30 2011-02-23 Lupin Limited Formulations à libération modifiée d'inhibiteurs de la hmg-coa réductase
WO2009112870A1 (fr) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Composition pharmaceutique comprenant de la rosuvastatine calcique et de l'hydroxyde de carbonate de magnésium pentahydraté comme stabilisant
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
MX2010013731A (es) * 2008-06-13 2011-01-14 Glaxo Group Ltd Cubierta de capsula de hidroxipropil celulosa.
DK2306982T3 (en) * 2008-06-27 2015-04-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
EP2138165A1 (fr) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique comportant de la statine
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (fr) 2009-08-13 2012-06-20 Synthon B.V. Comprimé pharmaceutique comprenant de la rosuvastatine calcique
WO2011086584A2 (fr) 2010-01-18 2011-07-21 Msn Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
EP2566465A2 (fr) 2010-05-04 2013-03-13 Mahmut Bilgic Formulations stables de rosuvastatine
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2698159A4 (fr) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk Préparation contenant de la pitavastatine et son procédé de production
RU2602911C2 (ru) * 2011-05-20 2016-11-20 Астразенека Юкей Лимитед Фармацевтическая композиция, содержащая кальциевую соль розувастатина
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
DK2851075T3 (da) * 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
JP2016514125A (ja) 2013-03-12 2016-05-19 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2016076280A1 (fr) 2014-11-11 2016-05-19 塩野義製薬株式会社 Comprimé multicouche contenant un médicament instable par rapport à la lumière
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
WO2017070612A1 (fr) 2015-10-23 2017-04-27 Lyndra, Inc. Systèmes à demeure gastriques pour libération prolongée d'agents thérapeutiques et leurs procédés d'utilisation
EP3243506A1 (fr) 2016-05-09 2017-11-15 Adamed sp. z o.o. Composition pharmaceutique
JP2019532947A (ja) 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
WO1990003973A1 (fr) * 1988-10-06 1990-04-19 Sandoz Ag Hydroxy acides, lactones et esters a substitution pyrimidinyle et compositions pharmaceutiques contenant ces composes
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (da) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabiliserede faste kemiske midler
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ATE228354T1 (de) * 1995-12-22 2002-12-15 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
PL344586A1 (en) 1998-06-05 2001-11-05 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
DK200001171A (da) 2001-07-27
CZ20002884A3 (cs) 2001-09-12
HUP0003110A3 (en) 2003-02-28
AP2002002409A0 (en) 2002-03-31
SK11792000A3 (sk) 2001-12-03
NZ531474A (en) 2007-04-27
EE04990B1 (et) 2008-04-15
NO327675B1 (no) 2009-09-07
PT102504A (pt) 2001-07-31
HRP20080525A2 (en) 2008-12-31
RU2002122752A (ru) 2004-03-10
EE05221B1 (et) 2009-10-15
GB2358582B (en) 2004-09-29
HU222578B1 (hu) 2003-08-28
FI111806B (fi) 2003-09-30
IS6254A (is) 2002-01-29
PL341853A1 (en) 2001-01-29
AU2005202392C1 (en) 2016-06-02
ITTO20000779A0 (it) 2000-08-04
ES2171123B1 (es) 2003-11-16
IL150513A (en) 2012-12-31
HRP20020632A2 (en) 2004-12-31
CN100528161C (zh) 2009-08-19
TR200701171T2 (tr) 2007-04-24
FI20001750A (fi) 2001-07-27
HK1048950A1 (zh) 2003-04-25
GB0001621D0 (en) 2000-03-15
RU2264210C2 (ru) 2005-11-20
NO20003968L (no) 2001-07-27
CR6568A (es) 2004-03-05
CA2639407A1 (fr) 2001-07-26
HK1040936A1 (en) 2002-06-28
UA77156C2 (en) 2006-11-15
DK1223918T3 (da) 2003-04-28
FI121365B (fi) 2010-10-29
DK178242B1 (da) 2015-09-28
AU781269B2 (en) 2005-05-12
IL187416A0 (en) 2008-02-09
JP2001206877A (ja) 2001-07-31
KR20030036492A (ko) 2003-05-09
DE10038110A1 (de) 2001-08-23
CH700184B1 (de) 2010-07-15
IS6480A (is) 2002-07-23
UA51853C2 (uk) 2002-12-16
CZ290167B6 (cs) 2002-06-12
FR2804025A1 (fr) 2001-07-27
SE0002827L (sv) 2001-07-27
DE10038110B4 (de) 2006-06-29
AU2005202392B2 (en) 2008-11-20
CZ20002883A3 (cs) 2000-10-11
DE60001371D1 (de) 2003-03-13
IS8620A (is) 2007-03-07
DK200001170A (da) 2001-01-27
SE0002826L (sv) 2001-07-27
PL196808B1 (pl) 2008-02-29
GB0019028D0 (en) 2000-09-27
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
AU738074B2 (en) 2001-09-06
PT102503A (pt) 2000-12-29
DE60001371T2 (de) 2004-01-22
ZA200003998B (en) 2000-08-14
ES2171123A1 (es) 2002-08-16
ITTO20000779A1 (it) 2002-02-04
NO20071303L (no) 2001-07-27
BR0003364A (pt) 2001-09-18
JP2007182452A (ja) 2007-07-19
TW553749B (en) 2003-09-21
BG66168B1 (bg) 2011-10-31
NO20003968D0 (no) 2000-08-04
AR023624A1 (es) 2002-09-04
JP3267960B2 (ja) 2002-03-25
CN1319396A (zh) 2001-10-31
EE200200411A (et) 2003-12-15
ME00202B (me) 2010-10-10
BG110353A (en) 2009-09-30
HUP0003111A3 (en) 2003-03-28
CZ298411B6 (cs) 2007-09-26
HU0003110D0 (en) 2000-10-28
HK1036934A1 (en) 2002-01-25
FR2804025B1 (fr) 2002-08-23
EP2266540A1 (fr) 2010-12-29
GB2358582A (en) 2001-08-01
EP2133070A1 (fr) 2009-12-16
PT1223918E (pt) 2003-06-30
WO2001054669A1 (fr) 2001-08-02
IL147870A (en) 2003-10-31
PT102503B (pt) 2004-02-27
SK283872B6 (sk) 2004-03-02
JP2001206847A (ja) 2001-07-31
US6316460B1 (en) 2001-11-13
WO2001054668A1 (fr) 2001-08-02
CA2315141C (fr) 2009-08-18
NL1015858C2 (nl) 2001-07-27
ES2155043B1 (es) 2001-12-01
AP2002002591A0 (en) 2002-09-30
NO2010005I1 (no) 2010-05-03
EE200900047A (et) 2011-04-15
EE05586B1 (et) 2012-10-15
SK11782000A3 (sk) 2001-12-03
SE523471C2 (sv) 2004-04-20
NO20003967L (no) 2001-07-27
YU5202A (sh) 2004-12-31
SE0002827D0 (sv) 2000-08-04
AR060248A2 (es) 2008-06-04
ES2155043A1 (es) 2001-04-16
EP1223918B1 (fr) 2003-02-05
AR025055A1 (es) 2002-11-06
AU781269C (en) 2006-11-30
GB0019029D0 (en) 2000-09-27
ATA13602000A (de) 2004-02-15
EP1223918A1 (fr) 2002-07-24
SE0002826D0 (sv) 2000-08-04
NO327554B1 (no) 2009-08-10
PL341855A1 (en) 2001-07-30
AU2005202392A1 (en) 2005-06-30
FR2795324A1 (fr) 2000-12-29
AU5184100A (en) 2001-08-02
NL1015859A1 (nl) 2001-07-27
FI20001749A (fi) 2001-07-27
SE523481C2 (sv) 2004-04-20
CR6687A (es) 2005-07-18
RS50201B (sr) 2009-07-15
CL2007001807A1 (es) 2008-01-18
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
EP2774609A1 (fr) 2014-09-10
KR20010077840A (ko) 2001-08-20
YU52902A (sh) 2006-01-16
AU6580000A (en) 2001-08-07
FI20105657A (fi) 2010-06-10
MEP33708A (en) 2010-10-10
AP1449A (en) 2005-07-28
BG65234B1 (bg) 2007-09-28
TR200201888T2 (tr) 2002-11-21
HK1036935A1 (en) 2002-01-25
CA2639407C (fr) 2011-09-13
HK1047052A1 (zh) 2003-02-07
BE1013413A3 (fr) 2001-12-04
CN1149997C (zh) 2004-05-19
CZ299105B6 (cs) 2008-04-23
HUP0003110A2 (hu) 2001-05-28
BG66159B1 (bg) 2011-09-30
ATE232088T1 (de) 2003-02-15
IS2805B (is) 2012-09-15
NO20003967D0 (no) 2000-08-04
EP1251831A1 (fr) 2002-10-30
SI1223918T1 (en) 2003-06-30
FI20001749A0 (fi) 2000-08-04
AP1879A (en) 2008-08-14
US6548513B1 (en) 2003-04-15
HUP0003111A2 (hu) 2002-02-28
EP2018853A1 (fr) 2009-01-28
AT412063B (de) 2004-09-27
HRP20020097A2 (en) 2002-06-30
CA2313783A1 (fr) 2000-10-16
HK1040936B (zh) 2010-06-11
ZA200003997B (en) 2000-08-14
TR200200270T2 (tr) 2002-06-21
HRP20020632B1 (en) 2010-12-31
DE10038108A1 (de) 2001-08-02
CN1282581A (zh) 2001-02-07
GB2358583B (en) 2002-02-06
CN101028268A (zh) 2007-09-05
KR100388713B1 (ko) 2003-06-25
BG106926A (bg) 2003-04-30
ATA13612000A (de) 2004-02-15
ITTO20000780A1 (it) 2000-11-04
AU2000264559A1 (en) 2001-08-07
NL1015859C2 (nl) 2001-10-16
HK1200368A1 (en) 2015-08-07
CA2313783C (fr) 2002-03-12
MY123650A (en) 2006-05-31
CH691347A5 (de) 2001-07-13
IS1940B (is) 2004-07-16
BE1013414A5 (fr) 2001-12-04
EE200200052A (et) 2003-04-15
FI20001750A0 (fi) 2000-08-04
KR100698333B1 (ko) 2007-03-23
CA2315141A1 (fr) 2001-07-26
KR20000072135A (ko) 2000-12-05
IL147870A0 (en) 2002-08-14
IL150513A0 (en) 2003-02-12
HU0003111D0 (en) 2000-10-28
MY122707A (en) 2006-04-29
BG106393A (en) 2002-07-31
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
BR0003365A (pt) 2001-09-18
JP4800988B2 (ja) 2011-10-26
HRP20020097B1 (en) 2010-12-31
TWI228050B (en) 2005-02-21
NO312434B1 (no) 2002-05-13
AT412062B (de) 2004-09-27
NZ519774A (en) 2004-04-30
CR10114A (es) 2008-08-21
AU5184200A (en) 2001-08-02

Similar Documents

Publication Publication Date Title
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
ITTO20010008A0 (it) Formulazione farmaceutica
NO20025450L (no) Ny farmasöytisk sammensetning
PT1242087E (pt) Composicoes farmaceuticas
NO20015175L (no) Farmasöytisk sammensetning
NO20033556L (no) Farmasöytiske formuleringer
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
FI20011478A (fi) Farmaseuttinen koostumus
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
FR2802423B1 (fr) Compositions pharmaceutiques
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
FI4488U1 (fi) Farmaseuttinen koostumus
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
MA26604A1 (fr) Compositions pharmaceutiques.
NO20032957L (no) Farmasöytisk emulsjonspreparat
MXPA03001857A (es) Composicones medicinales.
EE200200689A (et) Ravimkoostised

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20